Gilteritinib (XOSPATA®)
FLT3-mutated Relapsed/Refractory Acute Myeloid Leukemia
ApprovedCommercial; LCM (Maintenance therapy data generated)
Key Facts
Indication
FLT3-mutated Relapsed/Refractory Acute Myeloid Leukemia
Phase
Approved
Status
Commercial; LCM (Maintenance therapy data generated)
Company
About Kotobuki Pharmaceutical
A Japanese pharmaceutical company focused on manufacturing and developing small molecule drugs in gastroenterology, oncology, and neurology, with expertise in formulation development.
View full company profile